The Next Massive Wave in Metabolic Research After GLP-1?
For years, GLP-1-focused compounds dominated nearly every conversation surrounding metabolic and obesity-related research.
Amylin research in brief: Eloralintide, petrelintide and cagrilintide represent different approaches to amylin-pathway research. Their trial designs and development stages differ, so results from separate studies cannot establish a head-to-head winner.
Pharmaceutical companies quietly started shifting enormous amounts of money, development resources, and clinical attention toward a different category entirely:
Amylin receptor agonists.
What was once considered a relatively niche area of metabolic signaling research is now rapidly becoming one of the hottest sectors in the entire pharmaceutical industry.
Major pharmaceutical companies are advancing several different amylin-related research programs. Their development stages and evidence vary, so the dated company-by-company snapshot below is more informative than an unsourced market-growth forecast.
Research update, September 30, 2026: Lilly reported 48-week Phase 2b findings for EloraTZP (eloralintide plus tirzepatide) in 367 randomized adults with obesity or overweight and type 2 diabetes. The highest reported combination group had 23.3% mean body-weight reduction compared with 14.8% for tirzepatide alone and 3.0% for placebo using the efficacy estimand. The sponsor also reported gastrointestinal adverse events and treatment discontinuations. These combination findings support further research but are not head-to-head evidence of superiority over petrelintide, cagrilintide or other amylin programs, and do not establish properties of a separately sourced research vial.
The reason is simple:
Researchers increasingly believe amylin-focused compounds may play an important role in future satiety signaling, appetite regulation, gastric emptying modulation, and long-duration metabolic response research.
And unlike the early days of GLP-1 development, pharmaceutical companies are not wasting time.
They are moving aggressively.
Billions Are Already Pouring Into Amylin Research
The appeal is the range of approaches: petrelintide and eloralintide are being studied through amylin biology, while zenagamtide, formerly amycretin, combines GLP-1 and amylin receptor activity in one investigational molecule. Those different designs create different research questions, rather than a single race with identical candidates.
Over the last several years, some of the largest pharmaceutical companies in the world have entered the amylin agonist race.
Amylin research programs: company-by-company snapshot
Research checked November 4, 2026. Development status can change; the programs and study populations differ.
- Eli Lilly, eloralintide: a selective amylin receptor agonist in Phase 3 ENLIGHTEN-1; Lilly is also studying combinations with tirzepatide.
- Zealand Pharma and Roche, petrelintide: Zealand reports Phase 2 ZUPREME-1 and ZUPREME-2 topline results on its petrelintide pipeline page. Roche lists a Phase 3 petrelintide study as recruiting; the government registry also lists ZUPREME-4 as a separate Phase 3 study. A recruiting study has not yet established its results.
- Novo Nordisk, CagriSema and zenagamtide: CagriSema combines the amylin analog cagrilintide with semaglutide; Novo reports an FDA application for weight management and describes zenagamtide, formerly amycretin, as a dual GLP-1 and amylin receptor agonist in its November 2026 update.
- AbbVie and Gubra, ABBV-295: AbbVie presented Phase 1 findings and described advancement into Phase 2 development.
These are research and regulatory updates, not evidence that Xcel reference materials are medicines. Xcel materials are for laboratory research only, not for human or veterinary use.
Recent examples include:
- Roche and Zealand Pharma’s petrelintide agreement provides for total consideration to Zealand of up to $5.3 billion, including development and sales milestones that depend on future events.
- Eli Lilly continuing advancement of Eloralintide research following encouraging early-stage metabolic data.
- AbbVie and Gubra’s licensing agreement covers the investigational amylin analogue GUB014295, also known as ABBV-295.
- Novo Nordisk continuing development efforts involving CagriSema and other amylin-associated metabolic combination programs.
Amylin research has developed over many years, and several companies now have programs at different stages.
The snapshot above illustrates the range of current approaches without assuming every company is pursuing the same strategy.
That kind of industry-wide movement usually signals a major shift.
Why Researchers Are Paying Attention to Amylin Signaling
Part of the growing interest comes from how amylin signaling differs from traditional incretin-focused pathways.
Explore two distinct examples in our Petrelintide clinical evidence review and zenagamtide and amylin-pathway comparison.
For a separate look at appetite and reward research involving GLP-1 pathways, see our food noise and reward-signaling overview. The pathways and evidence are distinct. Researchers have increasingly explored how amylin receptor agonists may influence:
- Satiety signaling
- Appetite modulation
- Gastric emptying dynamics
- Meal size reduction
- Long-duration metabolic response models
- Combination pathway research involving GLP-1 agonists
Amylin candidates may be developed on their own or studied alongside GLP-1 therapies. They can compete as potential treatments while also offering a rationale for combination research.
Researchers are studying whether these pathways may complement one another in future metabolic research models.
That possibility has dramatically increased industry excitement.
Researchers are investigating how differences in molecular design and receptor selectivity affect the behavior of amylin-based candidates. Those properties and their safety profiles require evaluation for each individual compound.
This is one reason companies are now racing to develop next-generation amylin-focused research candidates.
Eloralintide Is Getting Increasing Attention
One of the more closely watched compounds in this emerging category is Eloralintide.
Eli Lilly’s eloralintide is being studied in clinical research. In a 48-week Phase 2 trial by Billings and colleagues, researchers reported weight changes versus placebo in adults without type 2 diabetes. Nausea and fatigue were also reported, with rates varying between study groups. These findings do not establish comparative safety against other amylin compounds.
What makes Eloralintide especially interesting is not simply the reduction data itself.
Researchers are increasingly interested in the broader implication:
Amylin-focused compounds may become a major component of future metabolic research strategies.
And interestingly enough, we actually discussed Eloralintide months ago before much of the recent industry attention accelerated.
In our earlier article:
“Cagrilintide vs Eloralintide: Which Amylin Receptor Agonist Shows Stronger Research Results?”
We explored how researchers were beginning to compare next-generation amylin compounds based on:
- Satiety signaling characteristics
- Administration structure
- Long-duration metabolic modeling
- Tolerability observations
- Research pacing and development timelines
At the time, relatively few research-focused websites were discussing Eloralintide in detail.
Now the broader pharmaceutical industry appears to be paying close attention.
Cagrilintide, Eloralintide, and Petrelintide: Why the Comparisons Matter
As more amylin-focused compounds continue entering development pipelines, researchers have increasingly started comparing compounds such as:
Before calling one amylin candidate the leader: Check which molecule and formulation were studied, whether it was used alone or in a combination, the trial population, duration, comparator and method used to estimate weight change. Results from separate programs cannot establish a head-to-head winner. Our petrelintide ZUPREME review and eloralintide guide document distinct evidence bases rather than treating the compounds as interchangeable.
- Cagrilintide
- Eloralintide
- Petrelintide
- Combination amylin/GLP-1 approaches
Each compound appears to bring slightly different characteristics involving duration, receptor interaction, tolerability modeling, and administration structure.
Direct comparisons remain difficult due to differing study durations, methodologies, administration protocols, and combination frameworks.
Still, one thing has become increasingly obvious:
The pharmaceutical industry no longer considers amylin agonists a small side category.
This is now one of the main battlegrounds in metabolic research.
The Amylin Analog Market Is Expanding Rapidly
Investment in amylin-related programs has attracted attention across the pharmaceutical industry.
The company programs and licensing agreements described above show substantial research activity. Future market size remains uncertain and depends on trial outcomes, regulatory decisions and other factors.
Several factors appear to be driving that growth:
- Increased obesity-related pharmaceutical investment
- Demand for next-generation metabolic pathways
- Combination therapy exploration
- Long-duration administration research
- Increased pharmaceutical competition
- Expanded global obesity treatment markets
The speed of this expansion has surprised even many industry analysts.
For years, GLP-1-focused research dominated the conversation almost entirely.
Now the industry appears increasingly interested in what comes next.
Some companies are pursuing triple agonists. Others are focusing on lean-mass preservation. And increasingly, many are placing enormous bets on amylin-related pathways.
Beyond GLP-1: What Happens Next?
The success of GLP-1-focused compounds completely changed the pharmaceutical landscape.
Now companies are aggressively searching for the next major breakthrough in metabolic research.
Whether amylin receptor agonists ultimately outperform existing GLP-1-focused approaches remains unknown.
But one thing is becoming very clear:
Amylin agonists are no longer experimental side conversations in obesity-focused research.
They are rapidly becoming one of the biggest areas of interest in the entire pharmaceutical industry.
And based on current pharmaceutical investment trends, that attention may only continue growing.